What is Alto Neuroscience's G&A?

Alto Neuroscience (ANRO) reported G&A of $6.84M in Q1 2026.

How has Alto Neuroscience's G&A changed year-over-year?

Alto Neuroscience's G&A increased by 20.0% year-over-year, from $5.7M to $6.84M.

What is the long-term trend for Alto Neuroscience's G&A?

Over 2 years (2023 to 2025), Alto Neuroscience's G&A has grown at a 66.1% compound annual growth rate (CAGR), from $7.52M to $20.75M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Alto Neuroscience ANRO G&A

G&A at other companies

Xenon PharmaceuticalsXENE

$23.82M+25.1%

Praxis Precision Medicines, Inc.PRAX

$27.87M+100%

MeiraGTx Holdings plcMGTX

$8.93M-4.7%

LBR

LB Pharmaceuticals Inc Common StockLBRX

$7.46M+148%

MapLight Therapeutics, Inc. MPLT

$10.82M+188%

Lantheus HoldingsLNTH

$57.53M+1.3%

Other financials

Income statement

See full

Operating income-$27.1M-73.1%

Net income-$26.2M-73.0%

EPS (diluted)-$0.80-42.9%

Balance sheet

See full

Cash & equivalents$264.3M+63.9%

Total debt$20.9M-17.2%

Total equity$243.4M+75.0%

Total assets$276.3M+60.7%

Cash flow

See full

Operating cash flow-$27.1M-63.6%

CapEx$556.0K+2,217%

Free cash flow-$27.6M-66.7%

Valuation

See full

Market cap$874.19M+1,335%

Enterprise value$630.81M-940%

Returns & leverage

See full

Return on equity-38.9%+0.9pp

Debt / equity0.1×-0.1×

Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alto Neuroscience's G&A?: Alto Neuroscience (ANRO) reported G&A of $6.84M in Q1 2026.
How has Alto Neuroscience's G&A changed year-over-year?: Alto Neuroscience's G&A increased by 20.0% year-over-year, from $5.7M to $6.84M.
What is the long-term trend for Alto Neuroscience's G&A?: Over 2 years (2023 to 2025), Alto Neuroscience's G&A has grown at a 66.1% compound annual growth rate (CAGR), from $7.52M to $20.75M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.